KR100769113B1 - 광화학적 내부이행을 통해 항원 제시 세포의 표면상에항원을 발현시키는 방법 - Google Patents
광화학적 내부이행을 통해 항원 제시 세포의 표면상에항원을 발현시키는 방법 Download PDFInfo
- Publication number
- KR100769113B1 KR100769113B1 KR1020017011688A KR20017011688A KR100769113B1 KR 100769113 B1 KR100769113 B1 KR 100769113B1 KR 1020017011688 A KR1020017011688 A KR 1020017011688A KR 20017011688 A KR20017011688 A KR 20017011688A KR 100769113 B1 KR100769113 B1 KR 100769113B1
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- cells
- antigen
- molecule
- photosensitizer
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 82
- 108091007433 antigens Proteins 0.000 title claims abstract description 82
- 102000036639 antigens Human genes 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 58
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 181
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 41
- 210000000172 cytosol Anatomy 0.000 claims abstract description 26
- 230000028993 immune response Effects 0.000 claims abstract description 20
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 230000030741 antigen processing and presentation Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000002255 vaccination Methods 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 11
- PBHVCRIXMXQXPD-UHFFFAOYSA-N chembl2369102 Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)S(O)(=O)=O)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1C=C2 PBHVCRIXMXQXPD-UHFFFAOYSA-N 0.000 claims description 10
- 150000004032 porphyrins Chemical group 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 229940124856 vaccine component Drugs 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 210000004020 intracellular membrane Anatomy 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical compound [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 claims description 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 3
- -1 4-sulfonatophenyl Chemical group 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 14
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000005012 migration Effects 0.000 abstract description 2
- 238000013508 migration Methods 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 12
- 238000002428 photodynamic therapy Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 210000003712 lysosome Anatomy 0.000 description 8
- 230000001868 lysosomic effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 230000012202 endocytosis Effects 0.000 description 6
- 210000001163 endosome Anatomy 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229940023041 peptide vaccine Drugs 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- ZUELZXZJXUXJCH-UHFFFAOYSA-N 3-[10,15,20-tris(3-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical compound Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 ZUELZXZJXUXJCH-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001159 endocytotic effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 101100091490 Caenorhabditis elegans hrp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003875 Ferrochelatase Human genes 0.000 description 1
- 108010057394 Ferrochelatase Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- XJCPMUIIBDVFDM-UHFFFAOYSA-M nile blue A Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4[O+]=C3C=C(N)C2=C1 XJCPMUIIBDVFDM-UHFFFAOYSA-M 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940125667 peptide vaccine candidate Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (33)
- 세포를 펩티드 항원 분자 또는 그 일부 및 광감작제와 접촉시켜, 상기 항원 분자 및 광감작제가 각각 상기 세포의 세포내 막으로 한정된 구획 내로 흡수되도록 하는 단계; 및상기 세포에 상기 광감작제를 활성화시키는데 유효한 파장의 광선을 조사하여, 세포를 사멸시키지 않으면서 세포내 구획의 막을 붕괴시켜 세포의 사이토졸 내로 상기 항원 분자를 방출시키고, 이어서 상기 방출된 항원 분자 또는 그 일부가 상기 세포의 표면 상에 제시되도록 하는 단계를 포함하는, 펩티드 항원 분자 또는 그 일부를 생체내에서 비인간 세포의 표면상에 발현시키거나 또는 시험관내에서 체액으로부터 얻어진 인간 세포 또는 비인간 세포의 표면상에 발현시키는 방법.
- 삭제
- 제 1 항에 있어서, 항원 분자가 면역반응을 촉진시킬 수 있는 분자인 방법.
- 제 3 항에 있어서, 항원 분자가 백신 항원 또는 백신 성분인 방법.
- 삭제
- 제 1 항에 있어서, 세포가 림프구, 수상돌기세포, 대식세포 및 암세포로 이루어진 그룹으로부터 선택된 항원 제시 세포인 방법.
- 제 1 항에 있어서, 광감작제가 포르피린, 프탈로시아닌, 푸르푸린, 클로린, 벤조포르피린, 나프탈로시아닌, 양이온성 염료, 테트라사이클린 및 라이소좀지향성 약염기 또는 그 유도체로 이루어진 그룹으로부터 선택되는 것인 방법.
- 제 7 항에 있어서, 광감작제가 테트라(4-술포네이토페닐)포르핀 (TPPS4), 인접한 페닐 고리들에 2-술포네이트기를 갖는 메조-테트라페닐포르핀 (TPPS2a) 또는 인접한 페닐 고리들에 2-술포네이트 기를 갖는 알루미늄 프탈로시아닌 (AlPcS2a)인 방법.
- 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에 있어서, 펩티드 항원 분자, 광감작제 또는 이들 둘다가 표적화제 또는 캐리어 분자에 결합된 것인 방법.
- 삭제
- 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에 있어서, 항원제시가 면역반응의 촉진을 야기시키는 것인 방법.
- 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에서 정의된 방법을 포함하는 백신접종 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 펩티드 항원 분자 또는 그 일부 및 광감작제를 포함하는, 세포의 표면 상에 상기 항원 분자 또는 그 일부를 발현시켜 면역반응을 촉진시키거나 세포독성 T 세포를 자극하는데 사용하기 위한 약제.
- 제 22 항에 있어서, 세포를 펩티드 항원 분자 또는 그 일부 및 광감작제와 접촉시켜, 상기 항원 분자 및 광감작제가 각각 상기 세포의 세포내 막으로 한정된 구획 내로 흡수되도록 하고; 상기 세포에 상기 광감작제를 활성화시키는데 유효한 파장의 광선을 조사하여, 세포를 사멸시키지 않으면서 세포내 구획의 막을 붕괴시켜 세포의 사이토졸 내로 상기 항원 분자를 방출시키고, 이어서 상기 방출된 항원 분자 또는 그 일부가 세포의 표면 상에 제시되도록 하는 약제.
- 제 22 항 또는 제 23 항에 있어서, 펩티드 항원 분자, 광감작제 및 세포가 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에 정의된 것인 약제.
- 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에서 정의된 방법에 의해 얻을 수 있는 세포집단을 포함하는, 면역반응을 촉진시키거나 세포독성 T 세포를 자극하기 위한 약제.
- 제 22 항 또는 제 23 항에 있어서, 백신접종에 사용되는 약제.
- 제 22 항 또는 제 23 항에 있어서, 바이러스성 질병, 암 또는 다발성 경화증의 치료에 사용되는 약제.
- 제 25 항에 있어서, 백신접종에 사용되는 약제.
- 제 1 항에서 정의된 펩티드 항원 분자 및 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에서 정의된 광감작제를 포함하는, 상기 항원 분자 또는 그 일부를 세포 표면상에 발현시키는데 있어서 동시에, 별도로 또는 순차적 사용을 위한 조합 제제로서의 제품.
- 제 1 항에서 정의된 펩티드 항원 분자를 함유하는 제 1 용기, 및 제 1 항, 제 7 항 및 제 8 항 중 어느 한 항에서 정의된 광감작제를 함유하는 제 2 용기를 포함하는, 세포의 표면상에 항원 분자 또는 그 일부를 발현시키는데 사용하기 위한 키트.
- 제 22 항 또는 제 23 항에 있어서, 펩티드 항원 분자가 백신 항원 또는 백신 성분인 약제.
- 제 22 항 또는 제 23 항에 있어서, 세포가 림프구, 수상돌기세포, 대식세포 및 암세포로 이루어진 그룹으로부터 선택된 항원 제시 세포인 약제.
- 제 22 항 또는 제 23 항에 있어서, 펩티드 항원 분자, 광감작제 또는 이들 둘다가 표적화제 또는 캐리어 분자에 결합된 것인 약제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9905911.5A GB9905911D0 (en) | 1999-03-15 | 1999-03-15 | Method |
GB9905911.5 | 1999-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010110664A KR20010110664A (ko) | 2001-12-13 |
KR100769113B1 true KR100769113B1 (ko) | 2007-10-22 |
Family
ID=10849643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017011688A KR100769113B1 (ko) | 1999-03-15 | 2000-03-10 | 광화학적 내부이행을 통해 항원 제시 세포의 표면상에항원을 발현시키는 방법 |
Country Status (19)
Country | Link |
---|---|
US (2) | US8216587B1 (ko) |
EP (1) | EP1223973B1 (ko) |
JP (1) | JP4922490B2 (ko) |
KR (1) | KR100769113B1 (ko) |
CN (1) | CN100379450C (ko) |
AT (1) | ATE419866T1 (ko) |
AU (1) | AU771990B2 (ko) |
CA (1) | CA2367357C (ko) |
CZ (1) | CZ299370B6 (ko) |
DE (1) | DE60041347D1 (ko) |
DK (1) | DK1223973T3 (ko) |
ES (1) | ES2319255T3 (ko) |
GB (1) | GB9905911D0 (ko) |
HU (1) | HU227604B1 (ko) |
MX (1) | MXPA01009316A (ko) |
NO (1) | NO331101B1 (ko) |
NZ (1) | NZ514228A (ko) |
PL (1) | PL208221B1 (ko) |
WO (1) | WO2000054802A2 (ko) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ303792B6 (cs) | 2000-11-29 | 2013-05-09 | Pci Biotech As | Zpusob zavedení molekuly do bunky |
EP1346059B1 (en) * | 2000-11-29 | 2012-05-23 | PCI Biotech AS | Photochemical internalization for delivery of molecules into the cytosol |
US20030031655A1 (en) * | 2001-02-08 | 2003-02-13 | Sequitur, Inc. | Methods of light activated release of ligands from endosomes |
GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
CA2474910A1 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
GB0613753D0 (en) | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
EP2079830B1 (en) * | 2006-10-04 | 2016-08-17 | Janssen Pharmaceutica NV | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
GB0811955D0 (en) * | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
GB0914286D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
GB201208548D0 (en) | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
US20160040128A1 (en) * | 2013-03-15 | 2016-02-11 | Pci Biotech As | Method |
KR102374556B1 (ko) * | 2013-08-28 | 2022-03-14 | 피씨아이 바이오테크 에이에스 | 백신접종 및 면역화를 위한 화합물 및 방법 |
GB2517707B (en) | 2013-08-28 | 2020-09-02 | Pci Biotech As | A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen |
WO2015028575A1 (en) * | 2013-08-28 | 2015-03-05 | Pci Biotech As | Immunisation method by photochemical internalisation |
US10973896B2 (en) * | 2014-04-11 | 2021-04-13 | Pci Biotech As | Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen |
GB201415250D0 (en) * | 2014-08-28 | 2014-10-15 | Pci Biotech As | Compound and method |
NZ729408A (en) | 2014-08-28 | 2021-12-24 | Pci Biotech As | A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine |
GB201503776D0 (en) | 2015-03-05 | 2015-04-22 | Pci Biotech As | Compound and method |
AU2017342086A1 (en) | 2016-10-14 | 2019-05-09 | Pci Biotech As | Treatment of cholangiocarcinoma with TPCS-2a induced photochemical internalisation of gemcitabine |
CN107029236B (zh) * | 2017-04-18 | 2020-04-10 | 中国医学科学院生物医学工程研究所 | 一种吲哚菁绿自组装纳米疫苗及制备方法 |
CN107217041B (zh) * | 2017-07-11 | 2020-05-15 | 深圳华云生物技术有限公司 | 具有高抗原呈递的dc细胞和抗原特异性t细胞及其制备方法和应用 |
GB201718631D0 (en) | 2017-11-10 | 2017-12-27 | Pci Biotech As | Method |
EP3823668A1 (en) | 2018-07-16 | 2021-05-26 | DCPrime B.V. | A combination product for use in tumor vaccination |
EP3958894A1 (en) | 2019-04-25 | 2022-03-02 | DCPrime B.V. | Methods of tumor vaccination |
CA3172447A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
GB202115451D0 (en) | 2021-10-27 | 2021-12-08 | Pci Biotech As | Method |
GB202301312D0 (en) | 2023-01-30 | 2023-03-15 | Pci Biotech As | Method and product |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
US5820872A (en) | 1992-11-18 | 1998-10-13 | Yale University | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor |
US5651993A (en) | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US6008211A (en) * | 1995-07-27 | 1999-12-28 | Pdt Pharmaceuticals, Inc. | Photoactivatable compounds comprising benzochlorin and furocoumarin |
KR100397131B1 (ko) * | 1997-05-07 | 2003-09-13 | 유니버시티 오브 브리티시 콜롬비아 | 광활성제로서 모노하이드로벤조포르피린 유도체의 에틸렌글리콜 에스테르 |
EP1346059B1 (en) | 2000-11-29 | 2012-05-23 | PCI Biotech AS | Photochemical internalization for delivery of molecules into the cytosol |
GB201208548D0 (en) | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
KR102374556B1 (ko) | 2013-08-28 | 2022-03-14 | 피씨아이 바이오테크 에이에스 | 백신접종 및 면역화를 위한 화합물 및 방법 |
-
1999
- 1999-03-15 GB GBGB9905911.5A patent/GB9905911D0/en not_active Ceased
-
2000
- 2000-03-10 NZ NZ514228A patent/NZ514228A/xx not_active IP Right Cessation
- 2000-03-10 AT AT00909489T patent/ATE419866T1/de active
- 2000-03-10 AU AU31771/00A patent/AU771990B2/en not_active Ceased
- 2000-03-10 CA CA2367357A patent/CA2367357C/en not_active Expired - Lifetime
- 2000-03-10 KR KR1020017011688A patent/KR100769113B1/ko not_active IP Right Cessation
- 2000-03-10 US US09/524,454 patent/US8216587B1/en not_active Expired - Fee Related
- 2000-03-10 MX MXPA01009316A patent/MXPA01009316A/es active IP Right Grant
- 2000-03-10 ES ES00909489T patent/ES2319255T3/es not_active Expired - Lifetime
- 2000-03-10 EP EP00909489A patent/EP1223973B1/en not_active Expired - Lifetime
- 2000-03-10 JP JP2000604874A patent/JP4922490B2/ja not_active Expired - Lifetime
- 2000-03-10 DE DE60041347T patent/DE60041347D1/de not_active Expired - Lifetime
- 2000-03-10 DK DK00909489T patent/DK1223973T3/da active
- 2000-03-10 CN CNB008050848A patent/CN100379450C/zh not_active Expired - Lifetime
- 2000-03-10 HU HU0202441A patent/HU227604B1/hu not_active IP Right Cessation
- 2000-03-10 WO PCT/GB2000/000903 patent/WO2000054802A2/en active IP Right Grant
- 2000-03-10 CZ CZ20013328A patent/CZ299370B6/cs not_active IP Right Cessation
- 2000-03-10 PL PL355015A patent/PL208221B1/pl unknown
-
2001
- 2001-09-14 NO NO20014491A patent/NO331101B1/no not_active IP Right Cessation
-
2012
- 2012-07-05 US US13/542,017 patent/US9737594B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
J. Exp. Med., 1997, Vol.186, No.8, p1213-1221(비교대상발명) * |
J.Exp.Med.186(8), 1213-21, 1997 * |
Also Published As
Publication number | Publication date |
---|---|
DE60041347D1 (de) | 2009-02-26 |
US8216587B1 (en) | 2012-07-10 |
CA2367357A1 (en) | 2000-09-21 |
ES2319255T3 (es) | 2009-05-06 |
US9737594B2 (en) | 2017-08-22 |
EP1223973A2 (en) | 2002-07-24 |
PL355015A1 (en) | 2004-03-22 |
CZ20013328A3 (cs) | 2002-03-13 |
NO20014491L (no) | 2001-11-14 |
JP2002541072A (ja) | 2002-12-03 |
DK1223973T3 (da) | 2009-05-04 |
CZ299370B6 (cs) | 2008-07-09 |
WO2000054802A2 (en) | 2000-09-21 |
AU3177100A (en) | 2000-10-04 |
HUP0202441A3 (en) | 2004-07-28 |
NO331101B1 (no) | 2011-10-03 |
CN100379450C (zh) | 2008-04-09 |
EP1223973B1 (en) | 2009-01-07 |
CA2367357C (en) | 2015-01-06 |
MXPA01009316A (es) | 2003-07-14 |
CN1376073A (zh) | 2002-10-23 |
HU227604B1 (en) | 2011-09-28 |
NO20014491D0 (no) | 2001-09-14 |
HUP0202441A2 (en) | 2002-10-28 |
NZ514228A (en) | 2004-01-30 |
JP4922490B2 (ja) | 2012-04-25 |
US20130330363A1 (en) | 2013-12-12 |
KR20010110664A (ko) | 2001-12-13 |
GB9905911D0 (en) | 1999-05-05 |
ATE419866T1 (de) | 2009-01-15 |
AU771990B2 (en) | 2004-04-08 |
WO2000054802A3 (en) | 2002-05-10 |
PL208221B1 (pl) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100769113B1 (ko) | 광화학적 내부이행을 통해 항원 제시 세포의 표면상에항원을 발현시키는 방법 | |
US8008077B2 (en) | Photochemical internalization for delivery of molecules into the cytosol | |
US6680301B2 (en) | Transfer of molecules into the cytosol of cells | |
AU2002220853A1 (en) | Photochemical internalization for delivery of molecules into the cytosol | |
RU2333246C2 (ru) | Фотохимическая интернализация для доставки молекул в цитозоль | |
AU2022218373A1 (en) | Method of delivering mrna in vivo | |
Dai | TH9402 mediated photodynamic therapy: implications for ex vivo purging and tumor vaccination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120921 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130926 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140924 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150922 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161011 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171011 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |